(Q71809643)

English

Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics

scientific article published on 01 May 1995

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7587053%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7587053%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

pharmacokinetics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

D. E. Nix

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7587053

26 May 2024

J. J. Schentag

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7587053

26 May 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7587053

26 May 2024

publication date

1 May 1995

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7587053%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

full work available at URL

https://api.elsevier.com/content/article/PII:073288939500074K?httpAccept=text/xml

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

https://api.elsevier.com/content/article/PII:073288939500074K?httpAccept=text/plain

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Diagnostic Microbiology and Infectious Disease

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7587053%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7587053%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7587053%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

71-76

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7587053%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Individualizing Gentamicin Dosage Regimens in Burn Patients with Gram-Negative Septicemia: A Cost–Benefit Analysis

1

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Gentamicin blood levels: a guide to nephrotoxicity

2

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

The in vitro activity of cefotaxime versus bacteria involved in selected infections of hospitalized patients outside of the intensive care unit

4

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Integration of Selected Pharmacologic and Microbiologic Properties of Three New -Lactam Antibiotics: A Hypothesis for Rational Comparison

5

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

6

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis

7

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime.

8

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

9

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Factors affecting theophylline clearances: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol

10

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis

13

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Cefmenoxime pharmacokinetics in patients with renal insufficiency

14

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Effect of protein binding on cefmenoxime steady-state kinetics in critical patients

15

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Principles of antibiotic tissue penetration and guidelines for pharmacokinetic analysis.

16

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Role for Dual Individualization with Cefmenoxime

17

1 reference

10.1016/0732-8893(95)00074-K

https://api.crossref.org/works/10.1016/0732-8893(95)00074-K

26 May 2024

Identifiers

10.1016/0732-8893(95)00074-K

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7587053%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7587053%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q71809643&oldid=2164944888"